Current Setup & Catalysts

Current Setup & Catalysts — The Trade Desk, Inc. (TTD)

The one-line read. After an ~86% drawdown, TTD is a genuinely cheap, net-cash, GAAP-profitable franchise trading on ~3.3x sales and ~11x forward adjusted EPS — but the entire debate now hangs on a single unresolved question the tape has not settled: is the fall from high-teens to ~12% revenue growth a self-inflicted Kokai-migration stumble that reverses, or Amazon-driven structural take-rate erosion that does not? Everything on this page is the bridge between that durable 5-to-10-year question and the near-term evidence path that will start to answer it. The single most decision-relevant event is the Q2 FY2026 print and the Q3 guide it carries, on August 6, 2026 — not because one quarter decides a decade, but because it is the next clean read on the one variable (revenue versus gross spend — the take-rate direction) that governs the whole thesis.

This is not a binary or distressed name. There is no maturity wall, no covenant, no going-concern question — zero debt and ~$1.3B net cash [7]. So no single print "decides the case." What the prints do is move the probability the market assigns to cyclical-versus-structural, and that probability is what the ~3x-sales multiple is arguing about.

The variant view, sized. On direction we are consensus-aligned — this is a watchlist name, cheap but growth-gated, and the Street's "Hold" (mean target $24.42 vs $19.53, ~25% upside) roughly captures that. Where we differ is on the near-term numbers and the skew:

• Modestly below Street on FY2026 revenue. Consensus FY2026 revenue of ~$3.18B (+9.7%) embeds an H2 re-acceleration: H1 lands near $1.44B (Q1 actual $689M plus a Q2 guide of "at least $750 million" [1]), which requires H2 to grow ~9% after Q2's guided ~8%. Given nine straight quarters of deceleration and management's own CPG/auto/tariff caveats, we model FY2026 revenue nearer +7–8% (~$3.10B), roughly 1–3% below consensus, and treat the Aug-6 Q3 guide as the number that resolves it.
• The skew into Aug 6 has flipped asymmetric to the upside. The market's estimate revisions are overwhelmingly negative (18–20 downward EPS cuts versus 0–2 up in the last 30 days; FY2026 adj. EPS trimmed from ~$2.07 to ~$1.85 over 90 days), and — critically — the earnings-day gap-downs are shrinking (−33% and −39% in early/mid-2025 to just −4.8% and −1.7% on the last two prints) even as growth kept sliding. Bad news is increasingly in the price. A stabilization or a take-rate-intact Q3 guide could re-rate hard (the historical up-gap base rate is +12% to +19%); a fresh sub-8% signal likely gaps down, but by less than history (est. −8% to −15%), not another −35%.

Sources: Q2 guidance and Q1 results per Q1 FY2026 earnings call [1]; consensus, target, and revision figures from the analyst-estimates and earnings-calendar data feeds (as reported); price-reaction base rate derived from the staged daily price series.

Where we are right now

Source: share price and consensus mean target from the market-data / analyst-estimates feed (as of 2026-07-11, ~36 analysts); next-earnings date from the earnings-calendar feed (2026-08-06). Company filings, as reported.

The stock crashed in three discrete guidance shocks, not on a reported-earnings collapse: −41% in February 2025 (the first revenue-guidance miss in 33 quarters [13]), −39% in August 2025, and a long grind lower through FY2025 results into mid-2026. Through all of it the business kept compounding: FY2025 revenue +18% to $2.90B, with a rising take rate of 21.6% (from 20.3%) as $13.4B of gross spend it never owns was recognized net into revenue [4][3]. This is a multiple de-rating, not an earnings impairment — which is exactly why the forward evidence path, not the backward tape, is what matters now.

What actually changed in the last 3–6 months

Sources: Q1 results and CSO departure per Q1 FY2026 call [1][2]; Section 20A claim and client concentration per FY2025 10-K [8][11]; one-member audit committee per 2026 proxy [10]; Publicis, CFO turnover, Nasdaq cure clock, CEO purchase, and Koa Agents from recent press (Ad Age, Adweek, StockTitan), as reported.

The historical earnings price-reaction base rate

Every "high impact" claim below is anchored here — how TTD actually moves on a print. Two facts dominate. First, the EPS surprise barely predicts the reaction — the moves are driven by revenue and the forward guide, not the headline beat/miss (Feb 2025 beat EPS and fell 33%; Aug 2025 was in-line on EPS and fell 39%). Second, the down-moves are shrinking — the last two prints moved just −4.8% and −1.7% despite continued deceleration, the signature of exhausted positioning. Average absolute earnings-day move over the last eight quarters: ~15%.

Source: EPS surprises from the earnings-calendar feed; next-day price moves derived from the staged daily price series (data/prices/) — not filing figures.

The live debate — what the market is watching now

Sources: take rate and value-added-service driver per FY2025 10-K MD&A [3]; revenue-may-not-track-spend risk [5]; CTV low-50s mix [1]; SBC add-back [6]; voting control [9]; one-member audit committee [10].

The near-term growth path is the spine of the whole debate. Consensus already models Q2 down to ~+8% and needs H2 to firm back to ~+9% to hit the full-year number — the Aug-6 Q3 guide is the first test of that bet.

Sources: quarterly YoY growth from company results (as reported); Q2 FY2026 point is the company's "at least $750 million" guide (~+8% vs the year-ago $694M) per the Q1 FY2026 call [1].

Ranked catalyst timeline

Ranked by decision value to an institutional investor — not by date. The most thesis-resolving event sits at the top whether it lands in weeks or quarters. Positioning context for the high-impact rows: no official short interest is reported for TTD, but the tape trades crowded-negative-momentum (deep ~19M-share ADV, estimates cut hard into the print), so a surprise in either direction is amplified — a short here carries real squeeze-into-a-beat risk given the +12% to +19% historical up-gaps.

Sources: Q2 guidance ("at least $750 million"), $164M Q1 buyback, and the CSO/OpenAI departure per the Q1 FY2026 call [1][2]; Section 20A claim per FY2025 10-K Note 13 [8]; one-member audit committee per 2026 proxy [10]; FY2025 buyback / zero debt per 10-K MD&A [7]; Q2/FY2026 consensus and next-earnings date from the analyst-estimates and earnings-calendar feeds; Nasdaq cure date, Google-remedy status, and Publicis settlement from recent press (StockTitan, AdExchanger, Ad Age), as reported — timing only, not a filing fact.

Impact view — what resolves the debate vs what only adds information

Only two of these actually close underwriting questions on a durable variable; the rest add information or move a quarter. Note the honest split: the events that resolve the near-term evidence path (the prints) are not the same as the events that resolve the durable thesis-breaker (governance/litigation), which no single quarter settles.

Sources: linked-thesis reads synthesized from the Bull, Bear, Long-Term Thesis and Forensic tabs; underlying facts cited elsewhere on this page — take rate [3], Section 20A [8], walled-garden risk [12].

The next 90 days

The window through mid-October is dominated by one hard high-impact date and one governance deadline; everything else is a soft window or continuous watchpoint. The first real catalyst is Aug 6 — there is no meaningful pre-earnings datable event.

Sources: earnings date from the earnings-calendar feed (2026-08-06); Nasdaq cure date, Google-remedy status, and litigation status from recent press, as reported; gross-margin/share-count context from the Q1 FY2026 call [1].

What would change the view

Over the next ~6 months, three observable signals would most move the underwriting debate — tied to the durable thesis, not to Stan's final verdict:

1. The take-rate direction (revenue vs gross spend), read across the Aug and Nov prints. Two quarters of revenue outgrowing gross spend with a take rate holding above ~22% would tilt the case Long — it is the direct evidence that the deceleration is cyclical, not structural [3]. Two quarters of revenue growing slower than gross spend — the failure mode management itself flags [5] — would confirm the bear and justify the de-rating.

2. The Q3 guide trajectory (given Aug 6). Flat-to-up sequential guidance is trough confirmation; a guide below ~8% extends the nine-quarter slope and reprices the name as a high-single-digit grower. This is the near-term evidence marker, and it is cleaner than any single reported number.

3. The governance/litigation path — the durable thesis-breaker. A clean Nasdaq cure with credible independents and a permanent CFO, plus a benign turn in the Section 20A case [8], would remove the standing discount on the ~49.9%-founder-controlled structure [9] that lowers trust in the very non-GAAP metrics the bull case leans on. Further oversight erosion or an adverse 20A step does the opposite — and unlike the growth question, no single print resolves it.

The upside wildcard sitting outside all three: a structural Google ad-tech remedy that widens the open-web pool — near-zero priced, and the one catalyst that could re-rate the multiple for reasons entirely outside TTD's own execution.